NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. - Wikidata - wikimedia - TriplyDB

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.

http://www.wikidata.org/entity/Q40053992

about

Regulation of immune cell function and differentiation by the NKG2D receptor Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Nutritional immunology: function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment NKG2D ligands as therapeutic targets Impact of the MICA-129Met/Val Dimorphism on NKG2D-Mediated Biological Functions and Disease Risks NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma Understanding of molecular mechanisms in natural killer cell therapy The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition Biology and clinical effects of natural killer cells in allogeneic transplantation.Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease Oncogenic stress sensed by the immune system: role of natural killer cell receptors Recognition of tumors by the innate immune system and natural killer cells.Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.NK cells: immune cross-talk and therapeutic implications.Present and Future of Allogeneic Natural Killer Cell Therapy The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation.The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines NKG2D ligands in tumor immunity.Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells Combination immune therapies to enhance anti-tumor responses by NK cells.MicroRNA-29b mediates altered innate immune development in acute leukemia.Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3.Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.Cellular immunotherapy for high-grade glioma.Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.Histone deacetylase inhibitors in the generation of the anti-tumour immune response.Use of allogeneic NK cells for cancer immunotherapy.Natural killer cell immune escape in acute myeloid leukemia.Combination strategies to enhance antitumor ADCC.Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.Novel immune modulators used in hematology: impact on NK cells

P2860

Q24635093-B5FECA0F-21DC-4EDE-B5CB-B89BA5EF5E53 Q26751011-B5F725A5-8925-4ABF-BAEB-A987E11A16B0 Q26753067-217C859F-1823-46DF-9D66-81655A84643B Q27014888-30F3AB07-B12B-4B8A-8CBF-9A81C1748C64 Q28066573-09202484-A9A9-4859-8379-2DFD7EFF89CC Q28080823-C9EA83EA-3540-4AD6-98D3-197696AC7EE0 Q28086976-B8346BC0-0BCF-4CBA-BCEE-BC8129D474A6 Q33584049-96A05AD4-6340-4776-8427-622788230792 Q33761979-9C64E021-A1D2-4EF5-A247-FB7C5D7CD3B1 Q33893173-02C20D9E-BD79-47F3-91A4-9BC75DC2532E Q34307792-530696F2-DFAE-4659-A5E9-87E863166479 Q34473267-DAEDB430-F4C3-4FE7-A898-4054C7E812A3 Q34496462-01ACA218-E247-48D5-9558-4E8D807726D6 Q34983200-77B4193A-7F49-4386-98B2-2FA3A7AC3726 Q35031677-571D3ACD-6D0A-43B4-A54D-5835F71695DD Q35053177-40A8F489-74E1-43D9-BDEB-F8A939997D81 Q35591444-960A3F0A-010B-4FA4-BC0E-09169B84EA5A Q35677351-F20AC5AD-F3D4-4167-83B9-5431B9CE327E Q36278732-4D6A2128-EAEA-4F81-81D5-A4DEA19876F6 Q36414249-295CD643-ED8F-4C0C-A417-2EED62F00AA2 Q36520715-FA466838-0880-484B-B322-904596FB9C7F Q36829028-B7414A5F-3817-4815-8611-BF5E8F5F4B6E Q37137360-EAAFB240-D264-47BA-B17A-40255630DC3B Q37287179-D297A87C-ED96-4182-B7D5-36C3F4FA5146 Q37406808-C20268A9-8E51-41E3-939D-01963D71062A Q37408550-D1D4839A-29C3-4438-B18F-CDE45B8C635E Q37452181-58EF175D-1B0F-40EF-BF84-D2FC00B0D5FB Q37559284-3A224158-AA06-4F8E-97C1-49DF692D024D Q37714638-59B97504-EF6F-4B32-B42F-30B1404C8DB1 Q37719306-21AA61DE-9D69-4270-B69E-2CC7C9C6B117 Q37779043-3D14B5FA-3854-4F98-A263-EEDFD4ACE083 Q37821337-31E1B71E-0887-4808-9195-D68BD123C278 Q37851972-6C532744-F3EB-44D6-A540-BFEFCA16FF4A Q37885284-BDD479BB-A713-4CF5-BBA0-D6C02EC91E84 Q37953826-0A52600B-2A14-4CD7-9B1A-153BE271C5B4 Q37957140-EA211D1B-F2F3-499A-AB15-578B8600C140 Q37996816-68C4F6CE-FE93-41F8-B350-BBEA39B4E84D Q38014085-CEEDC98D-AE79-494B-99A1-1584DB278250 Q38035301-4380AFF3-418F-4D16-8526-DE9609FFA14B Q38073760-A1395389-CF54-420A-AD3C-1B492328C7AA

P2860

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.

http://www.wikidata.org/entity/Q40053992

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

NKG2D ligand expression in AML ...... KIR-HLA class I specificities.

@en

type

label

NKG2D ligand expression in AML ...... KIR-HLA class I specificities.

@en

prefLabel

NKG2D ligand expression in AML ...... KIR-HLA class I specificities.

@en

P1433

Q40053992-51E794F0-85EF-4E44-83E7-6501BEB4597E

P1476

Q40053992-104E542C-AC24-488E-A5F0-E81EF889D8C5

P2093

Q40053992-10369875-C58B-426B-8D06-98527DDDEA6E

Q40053992-1B8A959C-1F87-42C2-9628-4936B629780C

Q40053992-234833D2-FA05-4DD8-8B61-DAF30C35AF7F

Q40053992-352DE824-EF8D-4DF2-AE59-327B46B257FD

Q40053992-3CAEB44F-6869-4D27-B7B7-3F7EB1E60169

Q40053992-586E6B12-4049-4978-9C7A-316A67C67050

Q40053992-80B2634E-8FA6-405D-BE38-C1EFCEA81473

Q40053992-A67E1960-F79A-4A03-B430-AFD11EAA3804

Q40053992-CCC41F8C-CBC8-43E5-A415-0D7C2758184E

Q40053992-D581F75B-591D-4CC0-AD6F-2F6E6A1DD54F

P304

Q40053992-4E58D2F3-0642-4323-B561-2E4139B863E1

P31

Q40053992-2852C992-6D2B-452C-9A3F-F93647130EB8

P356

Q40053992-77C5C78E-6E8C-40FD-AE51-E2E66D649211

P407

Q40053992-F992ED37-95D7-4A88-B958-98E0107EF63B

P433

Q40053992-645DB8E9-A1C2-4745-B535-23ACF5FA2DF7

P478

Q40053992-9CEDE63F-ACE9-4474-AA1D-8A375FDA2FA2

P50

Q40053992-73F993B2-9AFC-4DAF-803A-21959B1DBE6F

P577

Q40053992-BCF2730B-39E3-4832-9FE6-9D611C87D8C4

P5875

Q40053992-31364862-B573-4006-86D3-4F5835ABE721

P698

Q40053992-A5C45131-F278-4217-87C4-AB3ED742ED97

P356

BLOOD-2007-07-101311

P1433

P1476

NKG2D ligand expression in AML ...... KIR-HLA class I specificities.

@en

P2093

Aleksandra Wodnar-Filipowicz

http://www.w3.org/2001/XMLSchema#string

André Tichelli

http://www.w3.org/2001/XMLSchema#string

Arina Mathys-Schneeberger

http://www.w3.org/2001/XMLSchema#string

Bojana Durovic

http://www.w3.org/2001/XMLSchema#string

Christian P Kalberer

http://www.w3.org/2001/XMLSchema#string

Heike Himmelreich

http://www.w3.org/2001/XMLSchema#string

Jan Hofsteenge

http://www.w3.org/2001/XMLSchema#string

Monika Paluszewska

http://www.w3.org/2001/XMLSchema#string

Stefan Diermayr

http://www.w3.org/2001/XMLSchema#string

Ulrich Langenkamp

http://www.w3.org/2001/XMLSchema#string

P304

1428-1436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-07-101311

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5852472

http://www.w3.org/2001/XMLSchema#string

P698

17993609

http://www.w3.org/2001/XMLSchema#string